Synairgen plc (AIM: SNG)

London flag London · Delayed Price · Currency is GBP · Price in GBX
2.480
-1.265 (-33.78%)
Dec 20, 2024, 12:18 PM GMT+1
-65.89%
Market Cap 7.59M
Revenue (ttm) n/a
Net Income (ttm) -6.92M
Shares Out 202.66M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,218,803
Open 3.000
Previous Close 3.745
Day's Range 2.055 - 3.000
52-Week Range 2.055 - 10.000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Dec 27, 2024

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 36
Stock Exchange London Stock Exchange AIM
Ticker Symbol SNG
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.